National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.

Rapid Review

Commenced Completed Outcome
10/08/2015 01/09/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
17/11/2015  10/05/2016 Reimbursement Not Recommended

Following NCPE assessment of the Applicant’s submission, cost effectiveness of pertuzumab (Perjeta®) (in combination with trastuzumab and chemotherapy) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement.

Summary